NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024

A. Thompson, John; J. Schneider, Bryan; R. Brahmer, Julie; Abu Zaid, Mohammad; Achufusi, Amaka; Armand, Philippe; Berkenstock, Meghan; L. Bermas, Bonnie; Braaten, Tawnie; E. Budde, Lihua; Chokshi, Saurin; Crees, Zachary; Davies, Marianne; Deng, Changchun; Gesthalter, Yaron; D. Jain, Michael; Jain, Prantesh; Jallouk, Andrew; H. Kaffenberger, Benjamin; Khalil, Maya; G. Lechner, Melissa; Li, Tianhong; Marr, Alissa; McGettigan, Suzanne; P. McPherson, Jordan; Medina, Theresa; Mohindra, Nisha; J. Olszanski, Anthony; O. Oluwole, Olalekan; Pravin Patel, Sandip; Prosek, Jason; Reddy, Sunil; Reid, Pankti; Ryan, John; Ryder, Mabel; Salman, Huda; Santomasso, Bianca; Shofer, Scott; A. Sosman, Jeffrey; Wang, Yinghong; G. Zaha, Vlad; D. Zucker, Stephen; Lyons, Megan; Awotiwon, Ajibola; Hang, Lisa

doi:10.6004/jnccn.2024.0057

Public

NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024

Published in Journal of the National Comprehensive Cancer Network • Nov 1, 2024

Authors:

John A. Thompson

Bryan J. Schneider

Julie R. Brahmer

Abstract

The NCCN Guidelines for the Management of Immunotherapy-Related Toxicities are intended to provide oncology practitioners with guidance on how to manage the wide-ranging and potentially fatal toxicities that may occur with cancer immunotherapy. The guidelines address immune-related adverse events re...

Subject

Medicine

Immunotherapy

Guideline

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!